| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | buprenorphine (Espranor®) |
| Formulation | 2 mg and 8 mg oral lyophilisate |
| Reference number | 3621 |
| Indication | Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with Espranor oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction |
| Company | Martindale Pharma |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 01/11/2017 |